Earnings ·
Intellia Therapeutics reported second quarter 2026 financial results, including a net loss of $106.6 million and…
NTLAIntellia Therapeutics, Inc.
Intellia Therapeutics reported second quarter 2026 financial results, including a net loss of $106.6 million and ending cash reserves of approximately $628 million. The company announced positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema, showing an 87% reduction in attacks versus placebo, and expects FDA acceptance of the BLA in the second half of 2026 with a U.S. launch planned for early 2027. Additionally, enrollment was reinitiated in nex-z Phase 3 trials for ATTR amyloidosis, with MAGNITUDE-2 expected to complete by late 2026. Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on developing CRISPR gene editing therapies.